Drug interaction study for IPF patients taking multiple medications
NCT ID NCT06241560
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 4 times
Summary
This study looks at how pirfenidone changes the amount of a new medicine (BI 1015550) in the blood of adults with idiopathic pulmonary fibrosis (IPF). Twenty participants aged 40 and older will take both drugs over about a month. Researchers will measure blood levels to understand how the medicines interact, helping guide safe use together.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
LTD "Aversi clinic"
Tbilisi, 160, Georgia
-
LTD The First Medical Center
Tbilisi, 0180, Georgia
-
Renovatio Clinical-The Woodlands-69551
The Woodlands, Texas, 77380, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care